Controversies in treatment of chronic obstructive pulmonary disease
- 16 September 2011
- journal article
- review article
- Published by Elsevier BV in The Lancet
- Vol. 378 (9795), 1038-1047
- https://doi.org/10.1016/s0140-6736(11)61295-6
Abstract
No abstract availableFunding Information
- Boehringer Ingelheim
- GlaxoSmithKline
- Merck Sharp and Dohme
- Novartis
- MedImmune
- Pfizer
- AstraZeneca
- Chiesi Farmaceutici
This publication has 99 references indexed in Scilit:
- Susceptibility to Exacerbation in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2010
- Development and first validation of the COPD Assessment TestEuropean Respiratory Journal, 2009
- Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO indexThe Lancet, 2009
- Chronic obstructive pulmonary disease in non-smokersThe Lancet, 2009
- Outcomes for COPD pharmacological trials: from lung function to biomarkersEuropean Respiratory Journal, 2008
- From COPD to chronic systemic inflammatory syndrome?The Lancet, 2007
- The Nature of Small-Airway Obstruction in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2004
- The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2004
- Globalisation and the prevention and control of non-communicable disease: the neglected chronic diseases of adultsThe Lancet, 2003
- Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax, 2002